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ABSTRACT 
Objectives 
The aim of this study was to assess the test performance and clinical effectiveness of 
photodynamic diagnosis (PDD) compared with white light cystoscopy (WLC) in 
people suspected of new or recurrent bladder cancer. 
 
Methods 
A systematic review of randomised controlled trials (RCTs), non-randomised 
comparative studies or diagnostic cross-sectional studies comparing PDD with WLC.  
Fifteen electronic databases and websites were searched (last searches April 2008).  
For clinical effectiveness only RCTs were considered.   
 
Results 
Twenty-seven studies (2949 participants) assessed test performance.  PDD had 
higher sensitivity than WLC (92%, 95% CI 80 to 100% versus 71%, 95% CI 49 to 93%) 
but lower specificity (57%, 95% CI 36 to 79% versus 72%, 95% CI 47 to 96%).  For 
detecting higher risk tumours, median sensitivity of PDD (89% (6 to 100%)) was 
higher than WLC (56% (0 to 100%)) whereas for lower risk tumours it was broadly 
similar (92% (20 to 95%) versus 95% (8 to 100%)).  Four RCTs (709 participants) using 
5-aminolaevulinic acid (5-ALA) as the photosensitising agent reported clinical 
effectiveness.  Using PDD at transurethral resection of bladder tumour (TURBT) 
resulted in fewer residual tumours at check cystoscopy (relative risk (RR) 0.37, 95% 
CI 0.20 to 0.69) and longer recurrence-free survival (RR 1.37, 95% CI 1.18 to 1.59), 
compared with WLC.   
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Conclusions 
PDD detects more bladder tumours than WLC, including more high risk tumours.  
Based on four RCTs reporting clinical effectiveness, 5-ALA mediated PDD at TURBT 
facilitates a more complete resection and prolongs recurrence-free survival.   
 
 
Keywords: Systematic review, Meta-analysis, Diagnostic tests, Bladder cancer   
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INTRODUCTION 
Bladder cancer is the seventh most common cancer in the UK, affecting more than 
10,000 people each year (16).  The majority of diagnosed patients (75 to 85%) present 
with non-muscle invasive disease, which is characterised by a probability of 
recurrence at five years of 31 to 78% (1).  Flexible cystoscopy and voided urine 
cytology are currently the initial investigations of choice for patients with symptoms 
suggestive of bladder cancer.  If flexible cystoscopy confirms a bladder tumour or 
urine cytology shows malignant cells in the absence of an upper urinary tract 
urothelial tumour, a rigid white light cystoscopy (WLC) under general or regional 
anaesthesia is performed with transurethral resection of bladder tumour (TURBT) 
where applicable.   
The ultimate goal in the management of non-muscle invasive transitional cell 
carcinoma (TCC) of the bladder is the prevention of disease recurrence and 
progression.  Early cancer detection is an essential prerequisite of successful therapy.  
Unfortunately, small papillary bladder tumours and flat urothelial tumours such as 
carcinoma in situ (CIS) can easily be overlooked during conventional WLC.  Indeed, 
many of the recurrent tumours may be due to the persistence of residual tumour in 
the bladder after an incomplete TURBT.  Moreover, progression to muscle invasive 
or metastatic TCC is more likely to occur in those with concomitant CIS (1).  Non-
muscle invasive TCC of the bladder is one of the most expensive cancers to manage 
on a per patient basis, because of its high prevalence, high recurrence rate and the 
need for long-term cystoscopic surveillance.  The total cost of treatment and five year 
follow-up of patients with non-muscle invasive bladder cancer diagnosed during 
2001-2002 in the UK was over £35 million (12). 
Photodynamic diagnosis (PDD) is a technique that has been proposed to 
enhance tumour detection and resection.  The principle of PDD is based on the 
interaction between a photosensitising agent with a high uptake by tumour cells and 
light with an appropriate wavelength, which is absorbed by the agent and re-emitted 
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with a different wavelength (18).  We carried out a systematic review of the literature 
to assess the diagnostic performance of PDD compared with rigid WLC and its 
effects on patient outcomes.  
   
METHODS 
Search strategy 
Highly sensitive electronic searches, using both controlled vocabulary and free text 
terms, were undertaken.  The search strategies were originally developed for a 
systematic review (11) with a wider scope than this review and were designed to 
include retrieval of studies that assessed selected biomarker tests as well as PDD.  
We searched Medline (1966 - March  Wk 3 2008), Medline In-Process (1st April 2008), 
Embase (1980 –  Wk 13 2008), Biosis (1985- 27th March 2008), Science Citation Index 
(1970 – 1st April 2008), Health Management Information Consortium (March 2008) 
Cochrane Controlled Trials Register (The Cochrane Library, Issue 1 2008) as well as 
current research registers (National Research Register Archive (September 2007),  
Current Controlled Trials (March 2008), Clinical Trials (March 2008) and WHO 
International Clinical Trials Registry (March 2008)).  Additional databases searched 
included the Cochrane Database of Systematic Reviews (The Cochrane Library, Issue 
1, 2008), Database of Abstracts of Reviews of Effectiveness (March 2008), HTA 
Database (March 2008) and Medion (March 2008).  Searches were restricted to 
English language publications.  Details of the full strategies used for each database 
are available from the authors.  Reference lists of all included studies were scanned 
to identify additional potentially relevant studies.   
 
Study selection 
We included studies that assessed the test performance or clinical effectiveness of 
PDD compared with WLC in people suspected of having bladder cancer or 
previously diagnosed with non-muscle invasive bladder cancer and on follow-up 
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cystoscopic examination.  For test performance both randomised and observational 
(diagnostic cross-sectional or case-control) studies were included.  However case-
control studies in which the controls were healthy volunteers were excluded.  The 
reference standard was histopathological examination of biopsied tissue and studies 
had to report or allow the calculation of true and false positives and negatives.    For 
assessment of clinical effectiveness we included only RCTs and the outcomes 
considered were residual tumour at check cystoscopy, recurrence of bladder cancer 
over time following initial resection, and progression to muscle invasive disease.   
 
Data abstraction and quality assessment 
One reviewer screened the titles (and abstracts if available) of all reports identified 
by the search strategy.  Full-text copies of all studies deemed to be potentially 
relevant were obtained and two reviewers independently assessed them for 
inclusion.  One of three reviewers extracted details of study design, participants, 
index, comparator and reference standard tests and outcome data, and another 
checked the data extraction.  Disagreements were resolved by consensus or 
arbitration by another reviewer.   
Two reviewers independently assessed the quality of the included studies 
using a version of the quality assessment of diagnostic accuracy studies (QUADAS) 
tool adapted to make it more applicable for assessing reports of tests for bladder 
cancer.  QUADAS is a quality assessment tool for use in systematic reviews of 
diagnostic studies (17) but it is designed to be adapted to make it applicable to a 
specific review topic.  Disagreements were resolved by consensus or arbitration by a 
third reviewer.   
 
Quantitative data synthesis 
For studies of test performance, separate summary receiver operating characteristic 
(SROC) curves were derived for patient and biopsy level analysis.  These meta-
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analysis models were fitted using the hierarchical summary receiver operating 
characteristic (HSROC) model (9) in SAS 9.1.  Summary sensitivity, specificity, 
positive and negative likelihood ratios and diagnostic odds ratios (DORs) for each 
model were reported as point estimate and 95% confidence interval (CI).  Due to the 
clustering of biopsies within patients, the intervals from the biopsy level analyses 
were expected to be an underestimate of the true uncertainty. 
For studies reporting clinical effectiveness, dichotomous outcome data were 
combined as relative risk (RR).  In the absence of statistical heterogeneity, which was 
explored using chi-squared tests, I2 statistics and visual inspection, a fixed effect 
model was used.  Where there was evidence of heterogeneity, data were analysed 
using a random effects meta-analysis.   
 
RESULTS 
Trial flow 
Figure 1 shows the flow of studies through the review.  A list of the included 
diagnostic studies is shown in Supplementary Table 1 and a list of the included 
effectiveness studies is shown in Supplementary Table 2.   
 
Study characteristics and methodological quality 
The 27 diagnostic studies, published in 36 reports enrolled 2949 participants, with 
2807 contributing to the analysis.  Across 19 studies (2327 participants) reporting this 
information, 41% of the patients (n=946) were first time presenters with symptoms 
suspicious of bladder cancer while 59% (n=1381) had previously diagnosed bladder 
cancer.  Further details of the diagnostic studies are shown in Supplementary Table 
3.   
In the four RCTs reporting effectiveness outcomes, published in eight reports, 
the groups were randomised to WLC or PDD, while in the other studies the groups 
were randomised to WLC or WLC and PDD.  In Babjuk and colleagues (2), 33% 
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(20/60) of the PDD group and 45% (28/62) of the WLC group were newly presenting 
with symptoms suspicious of bladder cancer while 67% (40/60) of the PDD group 
and 55% (34/62) of the WLC group had previously diagnosed bladder cancer.  The 
remaining studies did not report this information.  All four studies used 5-
aminolaevulinic acid (5-ALA) as the photosensitising agent.  The follow-up periods 
for the studies were eight years, five years, two years and 10 to 14 days.  Kriegmair 
and colleagues (7) only aimed to evaluate residual tumour following TURBT.  
Further details of the effectiveness studies are shown in Supplementary Table 4.   
 Figure 2 summarises the results of the quality assessment for the diagnostic 
studies.  In all studies partial verification bias (all patients received a reference 
standard test) and test review bias (PDD and WLC were interpreted without 
knowledge of the results of the reference standard) were avoided.  However all 
studies were judged to suffer from incorporation bias, in that PDD was considered 
not to be independent of the reference standard test, as biopsies used in the reference 
standard test were obtained via the PDD procedure.  In all four studies reporting 
effectiveness outcomes it was unclear whether the sequence generation was really 
random or the treatment allocation was adequately concealed or whether outcomes 
assessors, care providers or patients were blinded.  
 
Quantitative data synthesis 
Diagnostic performance 
In the pooled estimates for patient level analysis, based on evidence from five 
studies, PDD had higher sensitivity than WLC (92%, 95% CI 80 to 100% versus 71%, 
95% CI 49 to 93%) but lower specificity (57%, 95% CI 36 to 79% versus 72%, 95% CI 
47 to 96%).  In the pooled estimates for biopsy level analysis, based on evidence from 
14 studies, PDD also had higher sensitivity than WLC (93%, 95% CI 90 to 96% versus 
65%, 95% CI 55 to 74%) but lower specificity (60%, 95% CI 49 to 71% versus 81%, 95% 
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CI 73 to 90%).  Figure 3 shows the SROC plot for studies reporting biopsy-level 
analysis.   
Across studies, the median sensitivity (range) of PDD compared with WLC 
for detecting lower risk, less aggressive tumours was broadly similar for patient level 
detection but higher for PDD for biopsy level detection (Table 1).  However, for the 
detection of more aggressive, higher risk tumours the median sensitivity of PDD for 
both patient and biopsy level detection was higher than WLC.  The higher sensitivity 
of PDD was also reflected in the detection of CIS alone, both for patient and biopsy 
level detection (Table 1).  
 
Type of photosensitising agent 
Most studies (n = 18) used 5-ALA as the photosensitising agent, while five used 
hexaminolaevulinate (HAL), two used hypericin and two used either 5-ALA or HAL.  
In patient based detection of bladder cancer, across four studies using 5-ALA and 
three using HAL, the median (range) sensitivity and specificity for 5-ALA was 96% 
(64 to 100%) and 52% (33 to 67%) respectively, compared with 90% (53 to 96%) 
sensitivity and 81% (43 to 100%) specificity for HAL.  In biopsy based detection of 
bladder cancer, across 15 studies using 5-ALA, the median (range) sensitivity and 
specificity for 5-ALA was 95% (87 to 98%) and 57% (32 to 67%), compared with 85% 
(76 to 94%) and 80% (58 to 100%) for HAL.   
 
Clinical effectiveness 
All four studies, involving 544 patients, reported residual tumour rate (pTa and pT1).  
The timing of cystoscopy following TURBT ranged from 10 to 14 days, to 10 to 15 
weeks after the initial resection.  Compared with WLC, the use of PDD was 
associated with statistically significantly fewer residual pTa and pT1 tumours (RR 
0.32, 95% CI 0.15 to 0.70 and RR 0.26, 95% CI 0.12 to 0.57 respectively), with an 
overall RR of 0.37 (95% CI 0.20 to 0.69).  Two studies involving 313 patients reported 
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recurrence-free survival at 12 and 24 months.  In the pooled estimates there was a 
statistically significant difference in favour of PDD at 24 months (RR 1.37, 95% CI 
1.18 to 1.59) but not at 12 months (RR 1.40, 95% CI 0.96 to 2.03).  The benefits of using 
PDD at TURBT in reducing tumour recurrence (pooled estimate RR 0.64, 95% CI 0.39 
to 1.06) and progression (pooled estimate RR 0.57, 95% CI 0.22 to 1.46) in the longer 
term were less clear, with the effect estimates favouring PDD without reaching 
statistical significance.   
 
DISCUSSION 
Statement of principal findings 
The pooled estimates for both patient and biopsy level analysis showed that PDD 
had higher sensitivity than WLC for detecting bladder cancer, but lower specificity.  
PDD also had a much higher sensitivity than WLC in the detection of more 
aggressive, higher risk tumours, including the detection of CIS alone.   With regard 
to effectiveness outcomes, compared with WLC the use of PDD during TURBT 
resulted in a statistically and clinically significant reduction in residual pTa and pT1 
tumours, longer recurrence-free survival of patients at two years following surgery 
and a longer interval between TURBT and tumour recurrence.  There was no clear 
evidence of a difference between PDD and WLC for the outcomes of tumour 
recurrence and progression in the longer term.  These results should be interpreted 
with caution as they are based on only a small number of studies. 
Adjuvant single-dose chemotherapy administered within the first 24 hours 
and ideally within the first six hours following TURBT is standard practice in the UK 
and much of Europe and was shown in a meta-analysis to reduce the relative risk of 
recurrence by 39% with a median follow-up of 3.4 years (15).  The administration of 
adjuvant intravesical therapy varied across the four RCTs and this made it more 
difficult to assess what the true added value of PDD might be in reducing bladder 
tumour recurrence rates in routine practice.  Although single-dose intravesical 
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chemotherapy can chemoresect small residual papillary marker lesions (10) it is 
known to be insufficient treatment for patients with intermediate and high-risk 
tumours including concomitant CIS, the types more likely to be detected by PDD 
(14). 
 
Strengths and limitations of the study 
In terms of strengths, a recently recommended HSROC model was employed which 
takes account of the trade off between true and false positives and models between 
study heterogeneity (8).  Pooled estimates of both patient and biopsy level detection 
were undertaken.  However biopsy level estimates were likely to be an 
underestimate of the true uncertainty due to clustering of biopsies within patients.  
For reports of clinical effectiveness we focused on RCTs.  In terms of limitations, non-
English language studies were excluded.  Based on screening English language titles 
or abstracts our searches identified 33 non-English language studies relating to PDD, 
some of which may have otherwise met the inclusion criteria.   
 
Implications for practice and research 
Our results suggest that the appropriate point in the clinical pathway for PDD to be 
used is in conjunction with rigid WLC during the initial TURBT, and possibly also in 
conjunction with rigid WLC during surveillance monitoring of high risk patients.  
The advantages of higher sensitivity (fewer false negative results, better detection of 
higher risk tumours) of PDD compared with WLC have to be weighed against the 
disadvantages of lower specificity (more false positive results, leading to additional 
unnecessary biopsies, potentially additional unnecessary investigations and the 
resulting anxiety caused to patients and their families).  In terms of the 
photosensitising agents used, HAL would result in fewer false positives than 5-ALA 
(based on data for both patient and biopsy-level analyses), although it is possible that 
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other factors apart from the agent used may also have contributed to the specificity 
values reported.   
 The literature continues to develop with regard to PDD in conference 
abstracts.  The study by Stenzl and colleagues (13) is noteworthy because it reports 
for the first time a HAL-based phase III multicentre RCT (PC B305) with clinical 
effectiveness outcomes.  Of 766 patients randomised in 28 European and USA 
centres, the recurrence rate at nine months was 36% following HAL-based TURBT 
and 46% following WLC-assisted TURBT (p=0.029).  Although full publication is 
awaited, the FDA in December 2009 approved HAL as an adjunct to WLC in the 
detection of non-muscle invasive bladder cancer.  
 We are aware of one other systematic review of PDD in non-muscle invasive 
bladder cancer, by Kausch and colleagues (5).  Although Kausch and colleagues 
considered studies published in English, French or German, of 21 reports of 17 trials 
included, only two were non-English language (both German).  Their review 
presented a patient-based meta-analysis of additional detection rate of PDD 
compared with WLC and considered effectiveness outcomes such as residual tumour 
and recurrence-free survival but did not report diagnostic accuracy measures such as 
sensitivity and specificity.  However, similar to our review, Kausch and colleagues 
(5) concluded that PDD detects more patients with bladder tumours, especially more 
with CIS, than WLC, and that more patients have a complete resection and a longer 
recurrence-free survival when diagnosed with PDD.      
 Further research is needed in the form of RCTs comparing PDD alone, with 
PDD or rigid WLC plus single dose adjuvant chemotherapy at TURBT in patients 
presumed to have non-muscle invasive bladder cancer.  Study design should take 
into account participant risk factors, for example smoking and age and allow 
outcomes to be reported based on risk categories at randomisation.  Clinical 
effectiveness outcomes should include residual tumour rates at first check 
cystoscopy, recurrence-free survival, tumour recurrence rates, time to first 
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recurrence, and progression.  Provision should be made for longer term (up to 10 
years) follow-up.   
 
 16 
Reference List 
 
 
 1.  Babjuk M, Oosterlinck W, Sylvester R, et al. Guidelines on TaT1 (non-muscle-
invasive) bladder cancer. [document on the Internet]. Arnhem: European 
Association of Urology; 2009. [accesssed January 2010] URL: 
http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/TaT1_BC.pdf 
 
 2.  Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-
induced fluorescence cystoscopy during transurethral resection reduces the 
risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005; 96:798-802. 
 3. Hendricksen K, Moonen PM, der Heijden AG, Witjes JA. False-positive 
lesions detected by fluorescence cystoscopy: any association with p53 and p16 
expression? World J Urol 2006; 24:597-601. 
 4.  Jichlinski P, Wagnieres G, Forrer M, et al. Clinical assessment of fluorescence 
cytoscopy during transurethral bladder resection in superficial bladder 
cancer. Urol Res 1997; 25:S3-S6. 
 5.  Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic Diagnosis in Non-
Muscle-Invasive Bladder Cancer: A Systematic Review and Cumulative 
Analysis of Prospective Studies. Eur Urol 2010; 57:595-606. 
 6.  Koenig F, McGovern FJ, Larne R, et al. Diagnosis of bladder carcinoma using 
protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 
1999; 83:129-135. 
 7.  Kriegmair M, Zaak D, Rothenberger KH, et al. Transurethral resection for 
bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy 
versus white light endoscopy. J Urol 2002; 168:475-478. 
 17 
 8.  Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test 
Accuracy Working Group. Systematic reviews of diagnostic test accuracy. 
Ann Intern Med 2008; 149:889-897. 
 9.  Macaskill P. Empirical Bayes estimates generated in a hierarchical summary 
ROC analysis agreed closely with those of a full Bayesian analysis. J Clin 
Epidemiol 2004; 57:925-932. 
 10.  Masters JRW, Popert RJM, Thompson PM, et al. Intravesical chemotherapy 
with epirubicin: A dose response study. J Urol 1999; 161:1490-1493. 
 11. Mowatt G, Zhu S, Kilonzo M, et al.  Systematic review of the clinical 
effectiveness and cost-effectiveness of photodynamic diagnosis and urine 
biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and 
follow-up of bladder cancer.  Health Technol Assess 2010;14(4).   
 
 12.  Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The 
economic consequences of prostate and bladder cancer in the UK. BJU Int 
2005; 95:59-63. 
 13.  Stenzl AS, Roessler WR, Fradet YF, et al. HEXVIX fluorescence cystoscopy 
improves detection and resection of papillary bladder cancer and reduces 
early recurrence: a multicentre prospective randomized trial. Abstract 1010. 
Eur Urol Suppl 2009; 8:373. 
 14.  Sylvester RJ, Oosterlinck W. An Immediate Instillation after Transurethral 
Resection of Bladder Tumor in Non-Muscle-Invasive Bladder Cancer: Has the 
Evidence Changed? Eur Urol 2009; 56:43-45. 
 15.  Sylvester RJ, Oosterlinck W, Van Der Meijden APM. A single immediate 
postoperative instillation of chemotherapy decreases the risk of recurrence in 
 18 
patients with stage Ta T1 bladder cancer: A meta-analysis of published results 
of randomized clinical trials. J Urol 2004; 171:2186-2190. 
 16.  UK bladder cancer statistics [webpages on the Internet]. Cancer Research UK; 
2010. [accessed January 2010] URL: 
http://info.cancerresearchuk.org/cancerstats/types/bladder/?a=5441 
 17.  Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development 
of QUADAS: a tool for the quality assessment of studies of diagnostic 
accuracy included in systematic reviews. BMC Med Res Methodol 2003; 
3(25):Nov 10. 
 18.  Zaak D, Karl A, Knuchel R, et al. Diagnosis of urothelial carcinoma of the 
bladder using fluorescence endoscopy. BJU Int 2005; 96:217-222. 
 
 
 
 
 
 19 
 
 
Table 1 Sensitivity of PDD and WLC in detecting stage/grade of tumour 
 
 PDD sensitivity % 
Median (range) 
WLC sensitivity %  
Median (range) 
Number of  
patients (biopsies) 
Number 
of studies 
Less aggressive/lower risk 
Patient based 
detection 
92 (20 to 95) 95 (8 to 100) 266 3 
Biopsy based 
detection 
96 (88 to 100) 88 (74 to 100) 1206 (5777) 7 
More aggressive/higher risk including CIS 
Patient based 
detection 
89 (6 to 100) 56 (0 to 100) 563 6 
Biopsy based 
detection 
99 (54 to 100) 67 (0 to 100) 1756 (7506) 13 
CIS 
Patient based 
detection 
83 (41 to 100) 32 (0 to 83) 563 6 
Biopsy based 
detection 
86 (54 to 100) 50 (0 to 68) 1756 (7506) 13 
 
Notes: 
1. The number of biopsies is the overall total reported by the studies. 
2. Number of biopsies.  In some studies more biopsies were taken for PDD than 
WLC and in these cases the higher number used for PDD has been used in the 
table.  In the less aggressive/lower risk category, Hendricksen and colleagues (3) 
reported 217 biopsies for PDD and 123 for WLC while Koenig and colleagues (6) 
reported 130 biopsies for PDD and 67 for WLC.  Hendricksen and colleagues and 
Koenig and colleagues were also included in the more aggressive/higher risk 
category, as was Jichlinski and colleagues (4), who reported 421 biopsies for PDD 
and 414 for WLC.  The studies by Hendricksen and colleagues, Jichlinski and 
colleagues and Koenig and colleagues were also amongst those reporting 
detection of CIS.       
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Figure 1 Flow of studies through review process 
 
 
 Titles and abstracts screened (n=5680) 
(for PDD and selected biomarkers) 
Not relevant for PDD review (n=5600) 
Full articles screened for PDD review (n=80) 
Excluded studies (n=36): 
Required outcomes not reported: 12 
Required study design not met: 10 
Required reference standard not met: 2 
Comparator not WLC: 1 
Retained for background information: 11 
44 reports of 31 studies included (diagnostic accuracy 
n=27, clinical effectiveness n=4) 
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Figure 2 Summary of quality assessment of the diagnostic studies (n=27)  
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Figure 3 SROC plot for biopsy level analysis (n=14 studies) 
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